Masuda et al.12 showed the benefit of capecitabine as an adjuvant treatment option for HER2-negative breast cancer patients with residual invasive disease after NCT and currently, the drug is approved for use in TNBC patients not achieving pCR in the U.S.. The gene discussed is ERBB2; the disease is breast carcinoma.